Drugs that contain Dabigatran Etexilate Mesylate
1. Pradaxa patents expiration
PRADAXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Dec, 2021
(2 years ago) | |
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(1 year, 9 months ago) | |
| US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(10 months ago) | |
|
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(4 months ago) | |
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(1 year, 10 months from now) | |
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(3 years from now) | |
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(3 years from now) | |
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(6 years from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Market Authorisation Date: 21 June, 2021
Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Treatment of venous thrombotic disease
Dosage: PELLETS;ORAL; CAPSULE;ORAL
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
